BeOne Extends BRUKINSA Access Program to 1,000 Patients in…

Event summary

BeOne Medicines, BeOne Care Foundation, and The Max Foundation renewed their partnership through 2028 to expand access to BRUKINSA for chronic lymphocytic leukemia (CLL) treatment in low- and middle-income countries.
The program aims to support approximately 1,000 patients cumulatively, up from 300 patients currently across Armenia, Ethiopia, and Nepal.
The renewal includes a $1 million grant from the BeOne Care Foundation to support patient care, physician engagement, and operational infrastructure over the next two years.
Potential expansion into additional countries, including Côte d’Ivoire, Malawi, Mongolia, Mozambique, Togo, and Zambia, based on operational readiness and evolving access priorities.

The big picture

This renewal underscores BeOne's commitment to addressing disparities in cancer care access. The program's expansion reflects broader industry trends toward equitable healthcare delivery, particularly in oncology. With CLL being the most common leukemia in adults, the initiative aims to bridge significant treatment gaps in underserved regions, aligning with global health equity goals.

What we're watching

Program Scalability: Whether the partnership model can sustainably expand access to innovative cancer treatment globally, reaching the projected 1,000 patients by 2028.
Geographic Expansion: The pace at which the program can be successfully implemented in new countries, given operational readiness and evolving access priorities.
Long-Term Impact: How the continuity of care for enrolled patients beyond the partnership term will affect long-term patient outcomes and program sustainability.